Abstract: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.

Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

Abstract: The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof.

Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.

Abstract: The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.

Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that bivalently bind to homodimeric IL-17C.

Abstract: As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.

Abstract: The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type 1 interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRP? receptor.

Abstract: Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins.

Abstract: The present invention provides antibodies that bind to CD47 with high affinity and specificity, and their use in treatment of a cancer.

Abstract: The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.

Abstract: Disclosed herein are antibody molecules binding specifically to C-KIT, antigen-binding portions thereof and medical uses therefor.

Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.

Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

Abstract: The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis.

Abstract: An object of the present invention is to provide a novel therapeutic or preventive agent for human T cell leukemia virus type-1 associated myelopathy (HAM) containing an anti-human CC-chemokine receptor 4 (CCR4) antibody or an antibody fragment thereof as an active ingredient, and characterized by the administration and dosage of the antibody or the antibody fragment thereof. The present invention relates to a therapeutic or preventative agent for HAM characterized in that an anti-human CCR4 antibody or an antibody fragment thereof is contained as an active ingredient and the antibody or the antibody fragment thereof is administered at a low dose.

Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.

Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Abstract: The invention relates to anti-human follicle-stimulating hormone receptor antibodies. The invention also relates to use of the anti-human follicle-stimulating hormone receptor antibodies in the treatment of cancer. The present invention also relates to a process for detecting cancerous cells and a process for diagnosis cancer. The present invention finds an application in the therapeutic and diagnostic medical technical fields.

Abstract: Provided herein are compositions and methods for detecting and/or targeting dysfunctional tumor antigen-specific CD8+ T cells in the tumor microenvironment for diagnostic, therapeutic and/or research applications. In particular, dysfunctional tumor antigen-specific CD8+ T cells are detected and/or targeted via their expression of cell surface receptors described herein, such as 4-1BB, LAG-3, or additional markers that correlate with 4-1BB and LAG-3 expression, such as markers differentially expressed on the surface of the T cells.

Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

Abstract: The present invention relates to a bispecific molecule comprising at least one anti-CD38 domain and at leak one anti-PD-L1 domain, which are capable of simultaneous binding to CD38 and PD-L1 antigens, respectively.

Abstract: The present invention relates to immunotherapeutic approaches to treating haematological cancers. In particular the invention relates to a method for treating a haematological cancer by targeting the 5T4 antigen. As such, the invention provides a method for treating haematological cancers comprising administering to a subject a 5T4-targeting agent. The invention also provides a 5T4-specific chimeric antigen receptor (CAR) and uses thereof in treating cancers.

Abstract: Antibodies that include a sulfatase motif-containing tag in a constant region of an immunoglobulin (Ig) heavy chain polypeptide are disclosed. The sulfatase motif can be converted by a formylglycine-generating enzyme (FGE) to produce a formylglycine (fGly)-modified Ig heavy chain polypeptide. An fGly-modified Ig heavy chain polypeptide of the antibody can be covalently and site-specifically bound to a moiety of interest to provide an antibody conjugate. The disclosure also encompasses methods of production of such tagged Ig heavy chain polypeptides, fGly-modified Ig heavy chain polypeptides, and antibody conjugates, as well as methods of use of same.

Abstract: The present invention relates to the combination of at least one agent and a reduced calorie intake for use in the treatment of a blood cancer. In particular the agent is a CD20 inhibitor Bruton's tyrosine kinase inhibitor, a phosphoinositide 3-kinase inhibitor, a class I and/class II histone deacetylase inhibitor, a non-taxane replication inhibitor or a proteasome inhibitor. The combination is advantageous in that it sensitize cancer cells to said agent while it protects normal cells from toxicity induced by said agent.

Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.

Abstract: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

Abstract: The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.

Abstract: Provided are novel human-derived dipeptide repeat (DPR) specific antibodies as well as synthetic variants and biotechnological derivatives thereof, preferably capable of binding C9ORF72 DPRs, as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for DPRs and DPR proteins such C9ORF72 DPRs are also disclosed. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.

Abstract: The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G.

Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.

Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.

Abstract: The present invention relates to bispecific anti-TNF-?/IL-17A antibodies and anti-TNF-? antibodies, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: An esterified cellulose ether is provided wherein the ester groups are phthalyl groups, the degree of substitution of phthalyl groups is from 0.02 to 0.18, the degree of neutralization of phthalyl groups is not more than 0.75, and the esterified cellulose ether has a solubility in water of at least 2.0 weight percent at 2° C.

Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Abstract: The present invention provides a PEG-ACS/M-siRNA nanocomposite application, and method for reducing the histamine content during fishmeal storage thereof. A small interfering ribonucleic acid (siRNA) is designed and prepared according to a histidine decarboxylase gene of Morganella morganii (Morganella morganii subsp. morganii KT), and the histidine decarboxylase gene has a sequence of SEQ ID No: 1. A PEG-ACS/M-siRNA nanocomposite is prepared by using a PEGylated arginine-modified chitosan as a carrier. A PEG-ACS/M-siRNA nanocomposite is added to fishmeal in a certain ratio. The method for reducing the histamine content during fishmeal storage has a significant inhibitory effect on the histamine content during fishmeal storage, and can reduce the histamine content in fishmeal by 49%-53%, which has great significance for the control of biogenic amines in fishmeal in the feed industry.

Abstract: The present relates generally to a method for stimulating the activation of an antigen presenting cell. The method includes activating antigen presenting cells by contacting the cells with an effective amount of a GC polymer that has a molecular weight of less than 420 kDa, followed by determining whether the antigen presenting cells are activated by measuring the amount of co-stimulatory marker CD40 expressed by the cells.

Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.

Abstract: Embodiments of the present invention are directed to kits, compositions and methods for modifying and altering poly-saccharide fillers and drug delivery systems with the application of hyaluronidase

Abstract: A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.

Abstract: A conjugated diene polymer satisfying following conditions (1) to (4): (1) the conjugated diene polymer has two or more peaks in a molecular weight distribution curve obtained by measurement with gel permeation chromatography (GPC); (2) the molecular weight distribution curve contains a peak (A) having a peak molecular weight of 500,000 to 2,500,000 and a peak (B) having a peak molecular weight of 150,000 to 600,000; (3) a total value of an area of the peak (A) and an area of the peak (B) is 70% or more of a total area of the molecular weight distribution curve; and (4) an absolute value of difference between a glass transition temperature of a conjugated diene polymer in the peak (A) (Tg (A)) and a glass transition temperature of a conjugated diene polymer in the peak (B) (Tg (B)) is 2° C. to 30° C.

Abstract: A disclosed three-dimensional modeling composition set includes a first composition, and a second composition, where at least one of a cured product of the first composition and a cured product of the second composition has water disintegratability, and when ST1 represents surface tension of the first composition and ST2 represents surface tension of the second composition, the following formula (1) is satisfied: IST1?ST2I?2 (1) where in the formula (1), the unit of the surface tension is mN/m. A method and an apparatus using the three-dimensional modeling composition set are also disclosed.

Abstract: An object of the present invention is to provide a novel method of producing a nonpolar olefin polymer (e.g., a copolymer of a nonpolar olefin and a polar olefin). The present invention provides a method of producing a polar olefin polymer or copolymer, the method including the polymerization step of polymerizing a polar olefin monomer using, as a catalyst, a polymerization catalyst composition containing: 1) a metallocene complex represented by Formula (I), which contains a central metal M that is scandium (Sc) or yttrium (Y), a ligand Cp* containing a cyclopentadienyl derivative and being bound to the central metal, monoanionic ligands Q1 and Q2, and W neutral Lewis bases L wherein W is an integer of 0 to 3; and 2) an ionic compound composed of a non-coordinating anion and a cation.

Abstract: Catalyst systems contain metal-ligand complexes according to formula (I): In formula (I), M is Ti, Zr, of Hf; n is 0, 1, 2, or 3; m is 1 or 2; each R1 and each R2 is independently chosen from (C1-C40)hydrocarbyl, (C1-C40)heterohydrocarbyl, (C1-C40)aryl, (C1-C40)heteroaryl, halogen, and —H; R1 and R2 are optionally covalently linked to each other; and each R3 is a hydrocarbon or heterohydrocarbon radical having an identity depending on the value of subscript m. The metal-ligand complexes may be incorporated as procatalysts in catalyst systems for polyolefin polymerization.

Abstract: A method produces a polymer composition with improved DC electrical properties. A cable can be surrounded by at least one layer that includes the polymer composition. The polymer composition includes a polyolefin, and the polymer composition has an electric conductivity of 0.50×10?15 S/m or less, when measured according to DC conductivity method using a tape sample consisting of the polymer composition.

Abstract: The present invention relates to polyethylene resin having excellent impact strength, and more specifically, to polyethylene resin exhibiting excellent impact strength and flexural strength, when prepared into a molded product.

Abstract: Methods for reducing gels and/or dome sheeting in gas phase polymerization processes and their resulting products are provided. The polymerization processes include polymerizing ethylene and one or more optional comonomers in a fluidized bed reactor in the presence of a metallocene catalyst, hydrogen, and at least one condensing agent.

Abstract: A solid precatalyst component for use in olefmic polymerization, includes titanium, magnesium, and an electron donor Ccompound; wherein: the electron donor compound is at least one compound represented by Formula (I).